Incyte (Nasdaq: INCY) Q2 2026 revenue jumps 38% as CMS Opzelura settlement lifts headline growth

Incyte Corporation (Nasdaq: INCY) reported second-quarter 2026 total revenue of $1.67 billion and total net sales of $1.49 billion, representing headline growth of 38% and 40% respectively over the prior-year period. Chief Executive Officer Bill Meury framed the quarter as evidence of “broad-based sales growth, continued pipeline progress and strategic business development,” with every marketed product contributing to top-line expansion. The headline figures, however, absorb a one-time, non-cash benefit of $246 million tied to the reversal of Opzelura accruals following the company’s agreement with the Centers for Medicare & Medicaid Services, without which underlying net sales grew 17% rather than 40%. Incyte also lifted its full-year 2026 revenue guidance to a range of $5.13 billion to $5.26 billion, closed the $1.25 billion cash acquisition of Vega Therapeutics in July for the Phase 3 von Willebrand disease antibody latarcibart, and quietly discontinued INCB160058 to prioritise its next-generation JAK2V617F programme. The central tension for institutional investors is whether the underlying commercial trajectory, stripped of the CMS accounting benefit and the incoming Vega IPR&D charge, is sufficient to sustain a share price that has already climbed roughly 69% over the past twelve months into a data-heavy second half.

How the Opzelura CMS settlement reshapes the reported growth number and what the underlying line actually says

The most consequential accounting event of the quarter is Incyte’s agreement with the Centers for Medicare & Medicaid Services to resolve litigation over the application of Medicaid rebate line-extension rules to Opzelura ruxolitinib cream. Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi, resolving a multi-year overhang on the dermatology franchise’s economics. The company estimates the total incremental impact on Opzelura net sales for full-year 2026 at $300 million to $310 million, comprising a one-time, non-cash $246 million reversal of previously established accrual balances through the first quarter of 2026, a $15 million second-quarter uplift from an improved gross-to-net profile, and a further $40 million to $50 million uplift expected across the third and fourth quarters.

The reporting effect is significant. Reported Opzelura net sales of $450 million grew 173% year on year, but underlying net sales, excluding the accrual reversal, were $204 million, an increase of 24% versus the prior-year period. Total net sales growth of 40% falls to 17% on the same basis. This gap matters because it separates a durable step-change in Opzelura profitability, which persists through the improved gross-to-net going forward, from a one-time accounting benefit that will not repeat. Analysts and shareholders who have modelled the reported growth rate as a run-rate signal are exposed to a distortion; those who read the disclosure carefully will focus on the $204 million underlying figure and the raised full-year Opzelura guidance range of $1.05 billion to $1.10 billion.

What the raised guidance implies about Opzelura, Jakafi and the operating expense base into year-end

Incyte’s revised full-year 2026 guidance framework is a study in contrasts. The company lifted its total net sales guidance to $5.13 billion to $5.26 billion from $4.77 billion to $4.94 billion previously, a midpoint uplift of roughly $340 million, of which the Opzelura CMS impact accounts for the majority. Opzelura full-year guidance rose to $1.05 billion to $1.10 billion from $750 million to $790 million, while Hematology and Oncology net sales guidance rose modestly to $860 million to $890 million from $800 million to $880 million. Jakafi and Jakafi XR guidance was left unchanged at $3.22 billion to $3.27 billion, an important tell that management is not extrapolating the second quarter’s 7% Jakafi growth into an upgraded trajectory for the flagship asset.

The operating expense line tells a different story. Total GAAP research and development and selling, general and administrative expense guidance was raised to $4.92 billion to $5.00 billion from $3.50 billion to $3.68 billion, an increase of approximately $1.4 billion at the midpoint. Total non-GAAP operating expense guidance rose in a similar range. The revised opex guidance reflects an in-process research and development expense of approximately $1.27 billion expected in the third quarter, associated with the Vega Therapeutics upfront payment and related transaction costs, together with $50 million of incremental ongoing research and development investment on latarcibart. In practical terms, the top-line uplift from the CMS settlement is being consumed several times over by the accounting recognition of an all-cash acquisition, meaning third-quarter and full-year 2026 GAAP earnings will look considerably weaker than the second-quarter run rate suggests, even as underlying operating performance continues to improve.

The market’s initial read appears to reflect this complexity. While reported revenue of $1.67 billion beat sell-side estimates of roughly $1.50 billion by 11%, and non-GAAP diluted earnings per share of $3.09 beat the $2.15 consensus by more than 40%, the full-year revenue guidance midpoint of $5.20 billion sits approximately 9% below the analyst estimate cluster that had built in more aggressive Opzelura flow-through and stronger core growth.

Why the closed Vega Therapeutics acquisition reshapes the Hematology franchise and the third-quarter accounting picture

The closing of the Vega Therapeutics acquisition in July is the most consequential capital allocation decision Incyte has disclosed in the current cycle. Under the stock purchase agreement, Incyte acquired all outstanding shares of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion in cash, with Star Therapeutics eligible to receive up to $750 million in additional payments contingent on the achievement of sales milestones. The transaction adds latarcibart, previously known as VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease, to Incyte’s late-stage pipeline.

The strategic rationale is defensible. Von Willebrand disease is the most common inherited bleeding disorder globally and is currently managed largely through factor replacement therapies. Data from the Phase 1/2 multidose study, presented at the 2026 International Society on Thrombosis and Haemostasis Congress in July, showed that once-monthly subcutaneous administration of latarcibart resulted in an 81% median reduction in annualised bleeding rate across all bleeding categories and all von Willebrand disease types. The global Phase 3 VIVID-6 study is now enrolling, structured as a single-arm crossover trial evaluating latarcibart as prophylaxis in patients with all types of the disease. Topline data from VIVID-6 are anticipated in early 2029, which places latarcibart on a longer runway than any of the other assets driving Incyte’s near-term earnings profile.

The financial mechanics are less flattering in the near term. The $1.25 billion upfront outflow is being funded from the company’s cash and marketable securities balance, which stood at $4.5 billion as of 30 June 2026, up from $3.6 billion at the end of 2025. Following the July closing, the pro forma cash position moves closer to $3.3 billion before further second-half operating cash generation, still comfortable but no longer growing. More visibly, the approximately $1.27 billion IPR&D charge will hit both GAAP and non-GAAP third-quarter results, temporarily distorting operating income and earnings per share comparisons in a way that mirrors the second-quarter Opzelura benefit in reverse.

How the Hematology and Oncology growth portfolio is starting to change the revenue mix beyond Jakafi

Total Hematology and Oncology net sales of $222 million represented growth of 69% over the prior-year period, driven by Niktimvo axatilimab-csfr, Monjuvi and Minjuvi tafasitamab, and Zynyz retifanlimab-dlwr. Niktimvo net sales of $60.3 million grew 67% year on year in chronic graft-versus-host disease. Monjuvi and Minjuvi net sales of $53.7 million grew 72%, with the recent frontMIND Phase 3 readout in first-line diffuse large B-cell lymphoma and high-grade B-cell lymphoma, published in The Lancet, providing a foundation for a potential US approval and launch in the first quarter of 2027. Global regulatory submissions for the frontline indication were submitted and accepted in the second quarter, and Minjuvi received a second approval in Japan in June for relapsed or refractory DLBCL in combination with lenalidomide.

Zynyz net sales of $49.9 million grew 460% off a small base, reflecting the rollout of the recent approvals in squamous cell carcinoma of the anal canal in the United States, Europe and Japan and Merkel cell carcinoma in North America, Europe and Switzerland. Iclusig ponatinib and Pemazyre pemigatinib remain smaller contributors at $34 million and $23 million respectively, growing 5% and 6%.

The strategic significance is that Jakafi and Jakafi XR net sales of $817 million, up 7% year on year and with paid demand growth of 9%, continue to account for approximately 55% of total net sales despite the introduction of the once-daily extended-release formulation in the second quarter following the May 2026 US approval for myelofibrosis, polycythemia vera and graft-versus-host disease. The 50% Novartis royalty rate reduction on US Jakafi sales, effective 1 January 2025 under the May 2025 settlement of the parties’ collaboration and license dispute, is now embedded in the reported economics. Incyte’s medium-term investment case therefore hinges on the newer Hematology and Oncology assets scaling faster than any deceleration in Jakafi’s contribution as it approaches loss of exclusivity in the next decade.

What the discontinuation of INCB160058 and the licensing of zilurgisertib say about pipeline discipline

Two smaller items in the release deserve more attention than they typically receive. The company discontinued further development of INCB160058, its first-generation JAK2V617F-targeted programme, following a comprehensive review of available data, in order to prioritise its next-generation JAK2V617F pipeline. The company also entered into an exclusive worldwide license agreement in the second quarter with Mirum Pharmaceuticals for zilurgisertib, an ALK2 inhibitor in development for fibrodysplasia ossificans progressiva, retaining an upfront payment, development and regulatory milestones, sales-based milestones and tiered royalties in the mid to high single-digit percentage range.

Together these decisions signal a management team willing to sacrifice sunk-cost commitments where the risk-adjusted return no longer justifies internal development. The INCB160058 termination is particularly noteworthy given the strategic centrality of the mutant CALR programme INCA033989, where updated Phase 1 data at the 2026 European Hematology Association Congress showed durable haematologic and symptom responses in essential thrombocythaemia and myelofibrosis patients. The registrational Phase 3 EXCALIBUR-ET2 study in mutant CALR positive essential thrombocythaemia patients resistant or intolerant to prior cytoreductive therapy was initiated in mid-2026, and a subcutaneous administration study using Halozyme’s ENHANZE technology was initiated in the second quarter under a global collaboration announced in July. The JAK2V617F platform therefore appears to be undergoing a controlled reset rather than a strategic retreat.

How the ten data readouts stack up against the current valuation

Incyte has now committed to ten clinical data readouts across the second half of 2026, including data from four registrational trials. The near-term catalyst list includes Niktimvo axatilimab in combination with ruxolitinib in newly diagnosed chronic graft-versus-host disease, further INCA033989 monotherapy and combination data in treatment-naive myelofibrosis, Phase 1 INCB161734 data in advanced colorectal cancer at the European Society for Medical Oncology Congress in Madrid in October, Phase 1 INCA33890 bispecific antibody data in microsatellite stable colorectal cancer at the same meeting, Phase 3 povorcitinib data in prurigo nodularis in the fourth quarter, Phase 2 povorcitinib data in asthma, and Phase 3 Opzelura data in hidradenitis suppurativa. Incyte expects a European regulatory decision on Opzelura in moderate atopic dermatitis in the third quarter following the June positive opinion from the Committee for Medicinal Products for Human Use, and anticipates a povorcitinib approval and launch in the European Union in late 2026 in hidradenitis suppurativa followed by a US launch in the first quarter of 2027.

The market appears to have priced in a substantial portion of this catalyst calendar. Shares closed near $117.67 heading into the release against a 52-week range of $69.69 to $119.60, giving a market capitalisation of approximately $23.5 billion, with a trailing price-to-earnings multiple of around 16.6 and a beta of 0.76. Sell-side coverage is split between nine Buy ratings and eleven Hold ratings among the twenty analysts surveyed by Google Finance, with a twelve-month average price target of $117.35, high of $140 following Bank of America’s July upgrade to Buy with a $136 target, and low of $99 at RBC Capital Markets, which retained a Sector Perform rating. Short interest of approximately 10.6 million shares represents 5.4% of the float with 4.7 days to cover, a modest overhang that does not suggest a directional consensus.

What should investors track as Incyte moves from CMS-inflated headline growth toward the 2027 launch cadence

The tests for the investment thesis over the next four quarters are specific rather than thematic. The first is the trajectory of underlying Opzelura net sales, stripped of the CMS accounting benefit, into the fourth quarter and the ramp of the moderate atopic dermatitis indication in Europe assuming approval in the third quarter. The second is whether Jakafi and Jakafi XR net sales growth accelerates modestly through the year as the extended-release formulation captures share, or whether the 7% second-quarter print represents a durable ceiling ahead of longer-term loss of exclusivity. The third is the pace of Monjuvi and Minjuvi conversion following the frontMIND submission, with the anticipated first-quarter 2027 US approval and launch in first-line diffuse large B-cell lymphoma potentially transforming the asset’s contribution.

The fourth test is whether the newer Hematology and Oncology growth trio, Niktimvo, Zynyz and Monjuvi/Minjuvi, can collectively grow into a $1 billion-plus annual revenue franchise by the end of 2027, providing a Jakafi-independent second growth engine ahead of the povorcitinib and latarcibart chapters. The fifth is how the market absorbs the Vega Therapeutics IPR&D charge in the third-quarter earnings release, given that GAAP operating income will show a significant reversal from the current run rate purely on accounting recognition of a strategically defensible acquisition. Investors should also track any further business development activity funded from the residual cash balance, particularly given the recent Halozyme, Vega and Edison Scientific transactions and the exclusive licensing of zilurgisertib to Mirum Pharmaceuticals, all of which suggest a management team actively rebalancing the portfolio.

The reported second-quarter numbers demonstrate that Incyte’s underlying franchise is genuinely growing at a double-digit pace and that the recent CMS resolution has meaningfully improved the long-term economics of the dermatology business. Whether that is enough to justify a valuation near the top of the 52-week range, with a sell-side target consensus effectively at spot, depends on the second-half readout calendar delivering registrational-quality data across multiple indications and on the 2027 launches meeting expectations without operating expense creep. The Vega acquisition and the raised guidance framework raise the ceiling of the outcome distribution; they also raise the bar for what the company must now deliver.

What should investors track as Incyte moves through the second-half readout calendar into 2027

• Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter, growing 38% and 40% respectively on a reported basis; underlying net sales growth of 17% excluding the one-time, non-cash $246 million Opzelura accrual reversal.
• Full-year 2026 total net sales guidance raised to $5.13 billion to $5.26 billion, driven principally by the $300 million to $310 million estimated incremental Opzelura impact from the CMS settlement.
• Opzelura net sales of $450 million in the second quarter, of which $204 million reflects underlying growth of 24% year on year; full-year Opzelura guidance raised to $1.05 billion to $1.10 billion.
• Jakafi and Jakafi XR net sales of $817 million, up 7% year on year, with full-year Jakafi guidance left unchanged at $3.22 billion to $3.27 billion, indicating no upward re-rating of the flagship asset by management.
• Hematology and Oncology portfolio net sales of $222 million, growing 69%, led by Niktimvo, Monjuvi and Minjuvi, and Zynyz; full-year Hematology and Oncology guidance raised modestly to $860 million to $890 million.
• Total GAAP operating expense guidance for research and development and selling, general and administrative combined raised by approximately $1.4 billion to $4.92 billion to $5.00 billion, reflecting the $1.27 billion Vega Therapeutics in-process research and development charge to be recognised in the third quarter.
• Vega Therapeutics acquisition closed in July for $1.25 billion upfront cash plus up to $750 million in sales-based milestones, adding latarcibart, a Phase 3 monoclonal antibody for von Willebrand disease with topline data anticipated in early 2029.
• Ten data readouts, including four from registrational trials, expected across the second half of 2026, with anticipated launches for Opzelura in moderate atopic dermatitis in Europe, povorcitinib in hidradenitis suppurativa in the European Union in late 2026 and the United States in the first quarter of 2027, and Monjuvi in first-line diffuse large B-cell lymphoma in the first quarter of 2027.
• INCB160058 development discontinued to prioritise the next-generation JAK2V617F pipeline; zilurgisertib exclusively licensed to Mirum Pharmaceuticals in exchange for upfront cash, milestones and mid to high single-digit royalties.
• Cash, cash equivalents and marketable securities of $4.5 billion at the end of June, reducing to approximately $3.3 billion pro forma for the Vega closing, ahead of continuing second-half operating cash generation and disciplined additional business development capacity.